Assessing genetic variations in patients with neuromyelitis optica and multiple sclerosis
Multicenter Prospective Interventional Study to Evaluate the Frequency of FCGR3A Gene Polymorphisms in Patients With Neuromyelitis Optica Spectrum Disorders, Myelin Oligodendrocyte Glycoprotein Antibody Disease, and Multiple Sclerosis.
This study is trying to see if certain genetic differences in the FCGR3A gene are more common in Italian adults with neuromyelitis optica, MOGAD, or multiple sclerosis.
Quick facts
| Phase | Not applicable |
|---|---|
| Study type | Interventional |
| Enrollment | 50 (estimated) |
| Ages | 18 Years and up |
| Sex | All |
| Sponsor | Fondazione Policlinico Universitario Agostino Gemelli IRCCS Academic / other |
| Locations | 1 site (Roma, Roma) |
| Trial ID | NCT06865274 on ClinicalTrials.gov |
What this trial studies
This study aims to evaluate the frequency of genetic polymorphisms in the FCGR3A gene among Italian patients diagnosed with neuromyelitis optica spectrum disorder (NMOSD), myelin oligodendrocyte glycoprotein antibody-associated disease (MOGAD), and multiple sclerosis (MS). Adult patients from various clinical centers in the Lazio region will be selected, and their medical records will be analyzed for clinical and neuroimaging data. A blood sample will be collected from each participant to assess the genetic variations that may influence disease pathology and immune response.
Who should consider this trial
Good fit: Ideal candidates for this study are adult patients aged 18 and older diagnosed with NMOSD, MOGAD, or MS.
Not a fit: Patients under 18 years of age or those unable to provide informed consent will not benefit from this study.
Why it matters
Potential benefit: If successful, this study could enhance understanding of genetic factors influencing neuromyelitis optica and multiple sclerosis, potentially leading to improved diagnostic and therapeutic strategies.
How similar studies have performed: While genetic studies in autoimmune diseases are common, this specific investigation into the FCGR3A polymorphism in the Italian population is novel and has not been extensively tested.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: * Adult patients diagnosed with MS, NMOSD, or MOGAD receiving care at participating centers * Patients aged ≥ 18 years * Ability to understand and sign informed consent Exclusion Criteria: * Individuals under 18 years of age * Inability to provide informed consent
Where this trial is running
Roma, Roma
- Fondazione Policlinico Universitario Agostino Gemelli IRCCS — Roma, Roma, Italy (Recruiting)
Study contacts
- Study coordinator: Massimiliano Mirabella, Neurology Associate Professor
- Email: massimiliano.mirabella@policlinicogemelli.it
- Phone: 0630155390
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.